Download Obatoclax Biodistribution in MLL Leukemia NOG Mouse Model PowerPoint Presentation

Login   OR  Register

Share on Social Media


Home / Health & Wellness / Health & Wellness Presentations / Obatoclax Biodistribution in MLL Leukemia NOG Mouse Model PowerPoint Presentation

Obatoclax Biodistribution in MLL Leukemia NOG Mouse Model PowerPoint Presentation

onlinesearch By : onlinesearch

On : Feb 24, 2014

In : Health & Wellness

Embed :

Login / Signup - with account for

  • → Make favorite
  • → Flag as inappropriate
  • → Download Presentation
  • → Share Presentation
  • Slide 1 - BACKGROUND MLL translocations (MLL+) , which are chemotherapy resistant, occur in ~80% of infant ALL and AML and are a poor prognostic factor in infant ALL. MLL translocations also occur in secondary leukemias after exposure to chemotherapeutic topoisomerase II poisons. Cell death pathways are desired targets of small molecule inhibitors since their deregulation plays an important role in chemotherapy resistance; e.g. imbalanced expression of BCL-2 family proteins leads to deregulated homeostatic binding between pro- and anti-apoptotic BCL-2 family members and impairs cell death. Obatoclax inhibits pro- and anti- apoptotic BCL-2 family protein interactions by binding to the BH3 pocket of the anti-apoptotic proteins. Obatoclax has potent single agent in vitro activity in MLL+ leukemias and cell lines. Adult phase I CLL trials indicate single agent activity with minimal toxicity. NOD-scid-IL-2Rnull (NOG) mice lack natural killer cell activity, resulting in superior engraftment of human leukemia xenografts compared to other immuno-deficient mouse strains. To construct obatoclax dose-exposure and tissue distribution relationships in NOG mouse xenograft model of MLL+ leukemia using an experimental design based on prior PK data from other strains of mice and adult Phase 1 trial target exposure data To determine the effect of leukemia and mouse strain on drug disposition Alena Y. Zhang1, Jeffrey S. Barrett1,2, Gwenn Danet-Desoyers2, Anthony Secreto2, Vu T. Nguyen, Cathy Keefer2, Xiaochuan Shan, 2 Ralph Bunte2, Manon Lavoie3, Pierre Beauparlant3 , Carolyn A. Felix1,2 1The Children’s Hospital of Philadelphia, 2University of Pennsylvania, Philadelphia, PA. 3Gemin X Pharmaceuticals, Inc., Montreal, Canada Obatoclax Biodistribution in MLL Leukemia NOG Mouse Model is Predicted by Modeling and Simulation and Shows High Tissue Penetration at Clinically Important Sites RESULTS (continued) DESIGN / METHODS (continued) III. Obatoclax biodistribution is extensive and sustained in murine equivalent sites of MLL+ leukemia Sustained drug retention in spleen, liver and brain, which are desired target sites of anti-leukemia activity. Brain:plasma ratios  2-10, indicate substantial CNS penetration. Higher ratios in the kidney for 1.2 mg/kg dose group suggest the potential for saturable elimination. Increasing tissue to plasma ratios with time in liver relative to other target organs with more consistent accumulation. Equilibrium of splenic uptake at 8 hours forms rationale for pre-treating with obatoclax 4 hours prior to chemotherapy to achieve chemosensitization in the upcoming preclinical diseased NOG mouse efficacy study. III. Experimental Design Figure 1: Schema of the PK study. NOG mice with established xenografts received single IV bolus dose of 1.2 or 4.8 mg/kg obatoclax. Concentrations were measured in plasma, spleen, liver, kidney and brain at indicated times using a validated LC-MS method II. Simulated pop-PK models show similar obatoclax exposure between mouse strains but slower elimination in the NOG Similar AUC24hr between strains at both doses. Greater than 3-fold longer half-life in NOG mice, suggesting slower elimination due either to strain differences, disease burden, or analytical detection limit at the lower concentration. Figure 2. Bi-phasic obatoclax disposition after IV bolus dosing in diseased NOG mice. Note good proportionality at both doses. Blue lines indicate in vitro obatoclax activity. IC90 IC50 Figure 3. Diagnostic plots of pop-PK model fit with observed concentrations in NOG mice. Left: Observed data versus population predicted (PRED) plasma concentrations. Right: Weighted residuals (WRES) versus population predicted (PRED) plasma concentrations. I. Modeling Approach Previously had constructed a pop-PK model using TK data from 3 single-dose studies in healthy Balb/C mice (courtesy of GeminX) via NONMEM with FO method (version 5, level 1.1, Globomax, Hanover, MD) (Zhang, 2007 ACCP Annual Meeting) Simulated obatoclax exposure in the NOG mouse based on adult CLL phase I target exposure (AUC24hr 180 ng•hr/mL) associated with peak ODNA release Assumptions based on model: 1.2 mg/kg and 4.8 mg/kg would achieve 100% and 400% of the target exposure Optimal sampling schedule to yield model-predicted parameters based on 7 time point design with “big rat” approach (destructive sampling consideration) Performed PK study in leukemia-bearing NOG mice and used NONMEM to develop a pop-PK model from experimental data RESULTS I. Pop-PK Model in MLL+ Leukemia NOG Mice A 2-compartment PK model best describes the distribution/elimination of obatoclax in NOG mice, similar to Balb/C. Exponential inter-individual variability model for CL, V1, Q and V2 and proportional error model for residual variability afford unbiased predictions of drug concentrations. Figure 5. Obatoclax tissue biodistribution in diseased NOG mice. NOG Balb/C 1.2 mg/kg 4.8 mg/kg Figure 4. Simulation of pop-PK models in mouse strains. Simulated plasma concentration-time profiles (n=100) illustrate median (solid line), 10th and 90th percentile (dotted lines) of the pop-PK models. Spleen Liver Kidney Brain II. MLL+ Leukemia Xenografts Established NOG mouse xenograft model of infant MLL/ENL+ bilineal leukemia that recapitulates the hyperleukocytosis and involvement of the CNS and other extramedullary sites in human MLL+ leukemia Performed simulations based on obatoclax pop-PK models in diseased NOG and healthy Balb/C mice Compared simulated secondary PK parameters using WinNonLin (Pharsight, Mountain View, CA)
Email Symbol Free PowerPoint Template

Email Symbol

Views : 244

Dentist Free PowerPoint Template


Views : 113

Medications Free PowerPoint Template


Views : 358

Easter Eggs Free PowerPoint Template

Easter Eggs

Views : 270

Guitar Free PowerPoint Template


Views : 530

Sperm Free PowerPoint Template


Views : 464

Mahatma Gandhi Free PowerPoint Template

Mahatma Gandhi

Views : 459

Blood Cells Free PowerPoint Template

Blood Cells

Views : 480

Baby Sleeping Free PowerPoint Template

Baby Sleeping

Views : 423

Earth Free PowerPoint Template


Views : 211

Stop Aids Free PowerPoint Template

Stop Aids

Views : 227

Massage SPA Free PowerPoint Template

Massage SPA

Views : 411

Coffee Free PowerPoint Template


Views : 425

Bales Free PowerPoint Template


Views : 276

Blue Eye Free PowerPoint Template

Blue Eye

Views : 289

Traffic Lights Free PowerPoint Template

Traffic Lights

Views : 302

Drugs Medicine Free PowerPoint Template

Drugs Medicine

Views : 662

Computing Information Technology Free PowerPoint Template

Computing Information Technology

Views : 250

Biology Free PowerPoint Template


Views : 281

USA Flag Free PowerPoint Template

USA Flag

Views : 195

Description : Available Obatoclax Biodistribution in MLL Leukemia NOG Mouse Model powerpoint presentation for free download which is uploaded by search an active user in belonging ppt presentation Health & Wellness category.

Tags : Obatoclax Biodistribution in MLL Leukemia NOG Mouse Model